Kraematon Investment Advisors Inc. Invests $222,000 in Altimmune, Inc. (NASDAQ:ALT)

Kraematon Investment Advisors Inc. acquired a new stake in Altimmune, Inc. (NASDAQ:ALT) during the fourth quarter, according to its most recent 13F filing with the SEC. The fund acquired 30,785 shares of the company’s stock, valued at approximately $222,000.

A number of other institutional investors also recently modified their holdings of ALT. Bank of New York Mellon Corp increased its position in shares of Altimmune by 28.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 243,808 shares of the company’s stock valued at $1,621,000 after purchasing an additional 54,154 shares during the last quarter. Commonwealth Equity Services LLC increased its position in shares of Altimmune by 9.0% during the second quarter. Commonwealth Equity Services LLC now owns 87,110 shares of the company’s stock valued at $579,000 after buying an additional 7,165 shares during the period. Rhumbline Advisers raised its position in shares of Altimmune by 25.8% in the 2nd quarter. Rhumbline Advisers now owns 107,446 shares of the company’s stock worth $715,000 after acquiring an additional 22,034 shares in the last quarter. Arizona State Retirement System lifted its position in Altimmune by 34.4% during the second quarter. Arizona State Retirement System now owns 19,847 shares of the company’s stock valued at $132,000 after buying an additional 5,081 shares during the period. Finally, Dimensional Fund Advisors LP lifted its position in Altimmune by 142.9% during the 2nd quarter. Dimensional Fund Advisors LP now owns 570,174 shares of the company’s stock valued at $3,791,000 after acquiring an additional 335,444 shares during the period. 78.05% of the stock is currently owned by hedge funds and other institutional investors.

Altimmune Price Performance

Shares of NASDAQ:ALT opened at $6.71 on Friday. The firm has a market capitalization of $477.22 million, a P/E ratio of -4.33 and a beta of 0.22. Altimmune, Inc. has a 1 year low of $5.28 and a 1 year high of $14.84. The business’s 50-day moving average is $8.05 and its 200 day moving average is $7.20.

Altimmune (NASDAQ:ALT) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.03. The business had revenue of $0.01 million during the quarter. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. During the same period last year, the firm earned ($0.39) EPS. On average, analysts expect that Altimmune, Inc. will post -1.35 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. HC Wainwright reissued a “buy” rating and set a $12.00 price objective on shares of Altimmune in a research report on Thursday, November 14th. Stifel Nicolaus assumed coverage on Altimmune in a research note on Wednesday, January 8th. They set a “buy” rating and a $18.00 price target for the company. Finally, UBS Group began coverage on Altimmune in a research note on Tuesday, November 12th. They issued a “buy” rating and a $26.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $19.71.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.